Nicox Focuses Research Activities on Novel NO-Donating PDE5 Inhibitors for Glaucoma and Enters into Collaboration with Novaliq on Innovative Topical Ophthalmic Formulations

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it will be focusing its research activities on topical nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitors and soluble guanylate cyclase (sGC) stimulators. As part of this focus, Nicox has entered into a research collaboration with Novaliq GmbH for the development of novel topical ophthalmic formulations of Nicox’s NO-donating PDE5 inhibitors based on Novaliq’s water-free enabling EyeSol® technology, for lowering intraocular pressure (IOP).

Read the full story at

Start typing and press Enter to search